Vertex Pharmaceuticals (VRTX) Finished Goods (2011 - 2012)
Vertex Pharmaceuticals' quarterly Finished Goods came in at $23.3 million in Q3 2012, up 94.18% year-on-year from $12.0 million in Q4 2011, and down 0.81% quarter-over-quarter from $23.5 million in Q2 2012.
Vertex Pharmaceuticals has reported Finished Goods for 2 years, with the latest figure at $23.3 million in Q3 2012.
- For the quarter ending Q3 2012, Finished Goods rose 94.18% year-over-year to $23.3 million; the trailing twelve-month figure through Sep 2012 stood at $23.3 million (up 94.18% YoY), and the FY2011 full-year result was $33.2 million, changed N/A from the prior year.
- Finished Goods for Q3 2012 stood at $23.3 million, down from $23.5 million in the prior quarter.
- The five-year high for Finished Goods was $33.2 million in Q4 2011, with the low at $12.0 million in Q3 2011.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 31.20 Bn | 31.20 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | 23.32 Mn |
| Jun 30, 2012 | 23.51 Mn |
| Mar 31, 2012 | 26.35 Mn |
| Dec 31, 2011 | 33.21 Mn |
| Sep 30, 2011 | 12.01 Mn |